U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07539441) titled 'A Study of Mirdametinib in People With Central Nervous System Tumors' on April 13.
Brief Summary: The purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytosis).
Study Start Date: April 10
Study Type: INTERVENTIONAL
Condition:
Central Nervous System Tumors
Glioma
Intervention:
DRUG: Mirdametinib
Mirdametinib is a highly selective and potent, non-ATP-competitive oral inhibitor of MEK1 and MEK2 kinases
Recruitment Status: RECRUITING
Sponsor: Memorial Sloan Kettering Cancer Center
Published by HT Digital Content Services with ...